Expert Interview
Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Ticker(s): CALT, TVTX, KDNYInstitution: Swedish Institute
- Nephrologist and Director of Swedish Polycystic Kidney Disease Center of excellence at Swedish Medical Center in Seattle.
- Manages around 60 patients with IgA nephropath and 100 patients with hyperphosphatemia.
- Research focuses on renal pathophysiology and polycystic kidney disease (PKD); investigator on several clinical trials of investigational treatments for autosomal dominant PKD.
How many patients with IgA Nephropathy do you currently manage?
Added By: chanell_adminWhy is Cidara listed as responsible for nefecon and not Calliditas?
Added By: user3f51b9e7The longer term data from the FSGS trial showed that sparsentan had no benefit on eGFR over the control arm, which was irbesartan. What does that tell us about IgA nephropathy?
Added By: catalin_adminThe liver monitoring that's required for sparsentan, do you expect the same thing will be the case for atrasentan?
What are the differences between sparsentan and atrasentan? And how would you compare them?
If you had to rate your level of excitement about each of these three drugs, Tarpeyo, Filspari, and atrasentan, on a 1 to 10 scale, what number would you choose and why for each?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
